Phase II clinical trials in oncology: Strengths and limitations of two-stage designs

Cancer Investigation

Volumn 24, Issue 4, 2006, Pages 404-412

  Schlesselman, James ^a,c   Reis, Isildinha ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bayesian methods; Clinical trials; Phase II studies; Two stage designs

Indexed keywords

ARTICLE; BAYES THEOREM; CANCER RESEARCH; CANCER THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; EXPERIMENTAL DESIGN; HUMAN; METHODOLOGY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TWO STAGE DESIGN;

BAYES THEOREM; CLINICAL TRIALS, PHASE II; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 33745296061     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900600705516     Document Type: Article

References (46)

1. Pharmaceutical Research and Manufacturers of America. Pharmaceutical Industry Profile 2005. (PhRMA, Washington, DC, March 2005), 4-5.
2. U.S. Food and Drug Administration Center for Drug Evaluation and Research. From test tube to patient: improving health through human drugs. (Food and Drug Administration, Rockville, MD, September 1999) 21. Accessed online August 11, 2005: http://www.fda.gov/cder
3. Pharmaceutical Research and Manufacturors of America. Pharmaceutical Industry Profile 2000. (PhRMA, Washington, DC, 2000), 35.
4. Food and Drug Administration. Online: http://www.fda.gov/cder/rdmt/ pstable.htm, Accessed August 11, 2005.
5. Horstmann, E.; McCabe, M.S.; Grochow, L.; et al. Risks and benefits of phase I oncology trials, 1991 through 2002. N. Engl. J. Med. 2005, 352, 895-904.
6. Thezenas, S.; Duffour, J.; Culine, S.; Kramar, A. Five-year change in statistical designs of phase II trials published in leading cancer journals. Eur. J. Cancer 2004, 40, 1244-1249.
7. Simon, R.; Wittes, R.E.; Ellenberg, S.S. Randomized phase II clinical trials. Cancer Treat. Rep. 1985, 69, 1375-1381.
8. Estey, E.H.; Thall, P.F. New designs for phase 2 clinical trials. Blood 2003, 102, 442-448.
9. Liu, P.Y.; LeBlanc, M.; Desai, M. False positive rates of randomized phase II designs. Control Clin Trials 1999, 20, 343-352.
10. Perrone, F.; Di Maio, M.; De Maio, E.; et al. Statistical design in phase II clinical trials and its application in breast cancer. Lancet 2003, 4, 305-311.
11. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 2000, 92, 205-216.
12. Mick, R.; Crowley, J.J.; Carroll, R.J. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin. Trials 2000, 21, 343-359.
13. Korn, E.L.; Arbuck, S.G.; Pluda, J.M.; et al. Clinical trial designs for cytostatic agents: Are new approaches needed? J. Clin. Oncol. 2001, 19, 265-272.
14. Green, S.; Benedetti, J.; Crowley, J. Clinical Trials in Oncology, 2nd ed. New York: Chapman & Hall/CRC, 2003, 65, 54-58.
15. Simon, R.M.; Steinberg, S.M.; Hamilton, M.; et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J. Clin. Oncol. 2001, 15, 1848-1854.
16. Hoekstra, R.; Verweij, J.; Eskens-Ferry A.L.M. Clinical trial design for target specific anticancer agents. Investigational New Drugs 2003, 21, 243-250.
17. Gehan, E. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J. Chron. Dis. 1961, 13, 346-353.
18. Fleming, T.R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38, 143-151.
19. Simon, R. Optimal two-stage designs for phase II clinical trials. Contr. Clin. Trials 1989, 10, 1-10.
20. Rubinstein, L.V. Therapeutic studies. Hematol/Oncol. Clinics North America 2000, 14, 849-876.
21. Cornfield, J. Sequential trials, sequential analysis and the likelihood principle. Amer. Statist. 1966, 20, 18-23.
22. Cornfield, J. The Bayesian outlook and its application. Biometrics 1969, 25, 617-657.
23. Royall, R. Statistical Evidence: A Likelihood Paradigm. New York: Chapman & Hall/CRC, 1997.
24. Ensign, L.G.; Gehan, E.A.; Kamen, D.S.; Thall, P.F. An optimal three-stage design for phase II clinical trials. Stat. Med. 1994, 13, 1727-1736.
25. Chen, T.T. Optimal three-stage design for phase II clinical trials. Stat. Med. 1997, 16, 2701-2711.
26. Schultz, J.R.; Nichol, F.R.; Elfring, G.L. Weed, S.D. Multiple-stage procedures for drug screening. Biometrics 1973, 29, 293-300.
27. Fleming, T.R.; Harrington, D.P.; O'Brien, P.C. Designs for group sequential tests. Control Clin. Trials 1984, 5, 348-361.
28. Atkinson, E.N.; Brown, B.W. Confidence limits for probability of response in multistage phase II clinical trials. Biometrics 1985, 41, 741-744.
29. Chang, M.N.; Therneau, T.M.; Wieand, H.S.; Cha, S.S. Designs for group sequential phase II clinical trials. Biometrics 1987, 43, 865-874.
30. Duffy, D.E.; Santner, T.J. Confidence intervals for a binomial parameter based on multistage tests. Biometrics 1987, 43, 81-94.
31. Jennison, C.; Turnbull, B.W. Group Sequential Designs with Applications to Clinical Trials. Boca Raton: Chapman & Hall/CRC, 2000.
32. Herndon, J.E. A design alternative for two-stage, phase II, multicenter cancer clinical trials. Control Clin. Trials 1998, 19, 440-450.
33. Bryant, J.; Day, R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 1995, 51, 1372-1383.
34. Thall, P.F.; Simon, R.; Estey, E.H. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat. Med. 1995, 14, 357-379.
35. Thall, P.F.; Simon, R.M.; Estey, E.H. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J. Clin. Oncol. 1996, 14, 296-303.
36. Case, L. D.; Morgan, T. M. Design of phase II cancer trials evaluating survival probabilities. BMC Medical Research Methodology 2003, 3, 6.
37. Aalen, O.O. Nonparametric inference for a family of counting processes. Ann. Stat. 1978, 6, 701-726.
38. Kaplan, E.L.; Meier, P. Nonparametric estimation from incomplete observations. J. Amer. Stat. Assoc. 1958, 53, 457-481.
39. Fayers, P.M.; Ashby, D.; Parmar, M.K.B. Tutorial in biostatistics. Bayesian data monitoring in clinical trials. Stat. Med. 1997, 16, 1413-1430.
40. Heitjan, D.F. Bayesian interim analysis of phase II cancer clinical trials. Stat. Med. 1997, 16, 1791-1802.
41. Spieghhalter, D.J.; Freedman, L.S.; Parmar, M.K.B. Bayesian approaches to randomized trials. J. Roy. Statist. Soc. Series A 1999, 157, 357-416.
42. Berry, D.A. Bayesian statistics and the efficiency and ethics of clinical trials. Stat. Science 2004, 19, 175-187.
43. Lee, P.M. Bayesian Statistics: An Introduction, 3rd Ed. London: Edward Arnold, 2004.
44. Thall, P.F.; Simon, R. A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials. Control Clin. Trials 1994, 15, 463-481.
45. Tan, S.B.; Machin, D. Bayesian two-stage designs for phase II clinical trials. Stat. Med. 2002, 21, 1991-2012.
46. Mayo, M.S.; Gajewski, B.J. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors. Control Clin. Trials 2004, 25, 157-167.